Niels Boone speaks to ecancer at the 2019 Biosimilars Educational Advanced Masterclass for Pharmacists (P-BEAM) in Zurich about the nocebo effect seen in clinical trials when examining the switch from the reference product to a biosimilar, and this can be improved from a patient's perspective.

He explains the concept of "one voice" communication and how this can be applied from the prescription to the administration of the drug.

He also outlines further improvements that can be made to refine this process.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

If you would like to learn more about biosimilar medicines, please visit our free e-learning modules here.